Last update: Jan. 29, 2017

Nedocromil Sodium

Very Low Risk for breastfeeding

Safe. Compatible.
Minimal risk for breastfeeding and infant.

It is administered by inhalation for prevention of asthma and atopic rhinitis and as eye drops for allergic conjunctivitis.

At latest update relevant published data on excretion into breast milk were not found.

Pharmacokinetic data (very low bioavailability after inhalation, orally or ophthalmic application with very low plasma levels achieved, moderately elevated molecular weight and a high protein-binding capacity) would render it rather unlikely a significant passage into breastmilk, which would also cause a poor absorption through the infant’s gut .

It is a well tolerated drug with indeed no side effects and none of them reportedly to be serious.

The small dose used and low plasma absorption of most inhaled preparations (either buccal or nasal), topically apply as ophthalmologic or dermatologic preparations, make it unlikely any passage in a significant amount into breastmilk.


We do not have alternatives for Nedocromil Sodium since it is relatively safe.

Suggestions made at e-lactancia are done by APILAM´s pediatricians and pharmacists, and are based on updated scientific publications.
It is not intended to replace the relationship you have with your doctor but to compound it.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.

Other names

Nedocromil Sodium in other languages or writings:


Variable Value Unit
Oral Bioavail. < 10 %
Molecular weight 415 daltons
Protein Binding 89 %
Tmax 0,5 hours
T1/2 1 - 3,3 hours


  1. AEMPS. Nedocromil. Ficha técnica. 2012 Full text (in our servers)
  2. Sanofi. Nedocromil. Drug Summary. 2008 Full text (in our servers)
  3. Neale MG, Brown K, Foulds RA, Lal S, Morris DA, Thomas D. The pharmacokinetics of nedocromil sodium, a new drug for the treatment of reversible obstructive airways disease, in human volunteers and patients with reversible obstructive airways disease. Br J Clin Pharmacol. 1987 Abstract

Total visits


Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write to us at

e-lactancia is a resource recommended by IHAN from Spain

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM